These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27168275)

  • 41. A cost-effectiveness and budget impact analysis of apremilast in patients with psoriasis in the Italian setting.
    Barbieri M; Loconsole F; Migliore A; Capri S
    J Med Econ; 2020 Apr; 23(4):362-370. PubMed ID: 31856619
    [No Abstract]   [Full Text] [Related]  

  • 42. Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
    Sobell JM; Foley P; Toth D; Mrowietz U; Girolomoni G; Goncalves J; Day RM; Chen R; Yosipovitch G
    Acta Derm Venereol; 2016 May; 96(4):514-20. PubMed ID: 26837052
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Favorable response to apremilast in a patient with refractory psoriasis verrucosa.
    Okazaki S; Osawa R; Nakajima H; Nakajima K; Sano S
    J Dermatol; 2019 Jun; 46(6):544-547. PubMed ID: 30957901
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Scalp psoriasis in a haemodialysis patient successfully treated with a half-dose of apremilast.
    Nagata M; Kamata M; Ohtsuki M; Sato S; Tada Y
    Eur J Dermatol; 2019 Jun; 29(3):341-342. PubMed ID: 31389793
    [No Abstract]   [Full Text] [Related]  

  • 45. Apremilast in the treatment of psoriasis and psoriatic arthritis.
    Gooderham M; Papp K
    Skin Therapy Lett; 2015; 20(5):1-6. PubMed ID: 26382906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study.
    Ighani A; Georgakopoulos JR; Walsh S; Shear NH; Yeung J
    J Am Acad Dermatol; 2018 Mar; 78(3):623-626. PubMed ID: 28989112
    [No Abstract]   [Full Text] [Related]  

  • 47. Drug survival of apremilast in a real-world setting.
    Kishimoto M; Komine M; Kamiya K; Sugai J; Ohtsuki M
    J Dermatol; 2019 Jul; 46(7):615-617. PubMed ID: 31180150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Real-World Clinical Experience With Apremilast in a Large US Retrospective Cohort Study of Patients With Moderate to Severe Plaque Psoriasis.
    Armstrong A; Levi E
    J Drugs Dermatol; 2017 Dec; 16(12):1240-1245. PubMed ID: 29240859
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Apremilast for the treatment of psoriatic arthritis.
    Varada S; Tintle SJ; Gottlieb AB
    Expert Rev Clin Pharmacol; 2014 May; 7(3):239-50. PubMed ID: 24702658
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of Psoriasis With Biologics and Apremilast in Patients With a History of Malignancy: A Retrospective Chart Review.
    Kahn JS; Casseres RG; Her MJ; Dumont N; Gottlieb AB; Rosmarin D
    J Drugs Dermatol; 2019 Apr; 18(4):. PubMed ID: 31013012
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term 52-week trends in apremilast safety outcomes for treatment of psoriasis in clinical practice: a multicentre, retrospective case series.
    Ighani A; Georgakopoulos JR; Shear NH; Walsh S; Yeung J
    Br J Dermatol; 2019 Jan; 180(1):211-212. PubMed ID: 30120892
    [No Abstract]   [Full Text] [Related]  

  • 52. Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.
    Torres T; Puig L
    Am J Clin Dermatol; 2018 Feb; 19(1):23-32. PubMed ID: 28597182
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
    Knuckles MLF; Levi E; Soung J
    J Dermatolog Treat; 2019 Aug; 30(5):430-434. PubMed ID: 30339049
    [No Abstract]   [Full Text] [Related]  

  • 54. Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report.
    Georgakopoulos JR; Ighani A; Yeung J
    J Cutan Med Surg; 2017; 21(5):452-456. PubMed ID: 28535721
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Apremilast as therapeutic option in a HIV positive patient with severe psoriasis.
    Sacchelli L; Patrizi A; Ferrara F; Bardazzi F
    Dermatol Ther; 2018 Nov; 31(6):e12719. PubMed ID: 30358044
    [No Abstract]   [Full Text] [Related]  

  • 56. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study.
    Rich P; Sigurgeirsson B; Thaci D; Ortonne JP; Paul C; Schopf RE; Morita A; Roseau K; Harfst E; Guettner A; Machacek M; Papavassilis C
    Br J Dermatol; 2013 Feb; 168(2):402-11. PubMed ID: 23362969
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Purpura Annularis Telangiectodes of Majocchi Associated With the Initiation and Rechallenge of Apremilast for Psoriasis Vulgaris.
    Kalik JA; Friedman H; Bechtel MA; Gru AA; Kaffenberger BH
    JAMA Dermatol; 2017 Nov; 153(11):1197-1198. PubMed ID: 28793154
    [No Abstract]   [Full Text] [Related]  

  • 58. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psoriasis vulgaris associated with systemic lupus erythematosus successfully treated with apremilast.
    Ichiyama S; Hoashi T; Kanda N; Hashimoto H; Matsushita M; Nozawa K; Ueno T; Saeki H
    J Dermatol; 2019 Jun; 46(6):e219-e221. PubMed ID: 30536461
    [No Abstract]   [Full Text] [Related]  

  • 60. Drug survival of apremilast in patients treated for psoriasis in a real-world setting.
    Lee EB; Amin M; Wu JJ
    J Am Acad Dermatol; 2018 Oct; 79(4):760-761. PubMed ID: 29588246
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.